AngioDynamics acquires FlowMedica renal therapy portfolio
This article was originally published in Clinica
Executive Summary
Cancer and peripheral vascular disease specialist AngioDynamics has boosted its diverse portfolio by purchasing for $1.75m in cash FlowMedica’s Benephit infusion products for delivering Targeted Renal Therapy (TRT). The deal will also see FlowMedica receive payments based on sales of Benephit systems in fiscal 2011.
Register for our free email digests: